We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.99%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$725M
AUM Growth
+$66.7M
Cap. Flow
+$16.4M
Cap. Flow %
2.26%
Top 10 Hldgs %
41.88%
Holding
145
New
38
Increased
32
Reduced
27
Closed
36

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$25.1M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.4M
3
AMGN icon
Amgen
AMGN
+$17.7M
4
BLUE
bluebird bio
BLUE
+$12.8M
5
VTRS icon
Viatris
VTRS
+$11M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$28.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.3M
3
SHPG
Shire pic
SHPG
+$11.3M
4
FOLD
Amicus Therapeutics
FOLD
+$9.93M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.8M

Sector Composition

Rank Sector Weight
1 Healthcare 72.21%
2 Technology 6.12%
3 Financials 1.97%
4 Industrials 1.58%
5 Consumer Discretionary 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
126
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-750,000
Closed -$65.8M
XFOR icon
127
X4 Pharmaceuticals
XFOR
$375M
– –
-639
Closed -$2.63M
XRAY icon
128
Dentsply Sirona
XRAY
$2.68B
– –
-2,500
Closed -$126K
MTVA
129
MetaVia Inc
MTVA
$7.33M
– –
-7
Closed -$3.13M
VBIV
130
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
– –
-22,209
Closed -$2.33M
EIGR
131
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-15,833
Closed -$4.68M
SCTL
132
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
– –
-406,080
Closed -$4.01M
PHXM
133
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
– –
-12,000
Closed -$2.52M
CLVS
134
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-168,000
Closed -$8.87M
ATHX
135
DELISTED
Athersys, Inc. Common Stock
ATHX
– –
-31
Closed -$1K
ENDP
136
DELISTED
Endo International plc
ENDP
– –
-550,000
Closed -$3.27M
GLIBA
137
DELISTED
GCI Liberty, Inc. Class A Common Stock (DE)
GLIBA
– –
-3,000
Closed -$159K
PTLA
138
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-200,000
Closed -$6.53M
BOLD
139
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-95,000
Closed -$2.85M
CMTA
140
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
– –
-200,000
Closed -$3.03M
TSRO
141
DELISTED
TESARO, Inc.
TSRO
– –
-106,175
Closed -$6.07M
VSTO
142
DELISTED
Vista Outdoor Inc.
VSTO
– –
-6,000
Closed -$98K
CELG
143
DELISTED
Celgene Corp
CELG
– –
-319,000
Closed -$28.5M
LJPC
144
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-260,000
Closed -$7.74M
2 3 4 5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2018 Portfolio in Review

As of Q2 2018, Sphera Funds Management held 145 positions worth $725M, up 10% from $659M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sphera Funds Management's Q2 2018 filing shows 38 new, 32 increased, 27 reduced and 36 closed positions. Its largest new stake was Gilead Sciences: 355,000 shares worth $25.1M. The largest sale was Celgene Corp, an estimated $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 75% a quarter earlier, followed by Technology and Financials.

  • Sphera Funds Management's largest Q2 2018 buy was Gilead Sciences: 355,000 shares worth $25.1M.
  • Sphera Funds Management added most to Viatris in Q2 2018, an estimated $11M increase.
  • Sphera Funds Management's biggest Q2 2018 reduction was Shire pic, cutting an estimated $11.3M.
  • Sphera Funds Management fully exited Celgene Corp in Q2 2018, selling an estimated $28.5M.
  • Sphera Funds Management's ten largest holdings make up 42% of its $725M portfolio in Q2 2018.
  • Sphera Funds Management opened 38 new positions and closed 36 in Q2 2018.
  • Sphera Funds Management's portfolio value rose 10% quarter-over-quarter to $725M.

Based on Sphera Funds Management's 13F filing for Q2 2018, filed 13 Aug 2018.